Boundless Bio
BOLD
55 hedge funds and large institutions have $46.1M invested in Boundless Bio in 2024 Q3 according to their latest regulatory filings, with 12 funds opening new positions, 11 increasing their positions, 17 reducing their positions, and 4 closing their positions.
200% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 4
17% more funds holding
Funds holding: 47 → 55 (+8)
2.54% less ownership
Funds ownership: 62.18% → 59.64% (-2.5%)
14% less capital invested
Capital invested by funds: $53.4M → $46.1M (-$7.37M)
35% less repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 17
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$618K |
| 2 |
PHS
PFM Health Sciences
San Francisco,
California
|
+$362K |
| 3 |
Northern Trust
Chicago,
Illinois
|
+$209K |
| 4 |
UOC
UBS O'Connor
Chicago,
Illinois
|
+$193K |
| 5 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$181K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$908K |
| 2 |
ECM
ExodusPoint Capital Management
New York
|
-$718K |
| 3 |
Ensign Peak Advisors
Salt Lake City,
Utah
|
-$642K |
| 4 |
Morgan Stanley
New York
|
-$569K |
| 5 |
BlackRock
New York
|
-$393K |
BOLD Hedge Fund Activity: Q3 2024 in Review
55 of the 6,965 institutional investors tracked by Wall St. Rank reported a position in Boundless Bio (BOLD) for Q3 2024, worth a combined $46.1M — down 14% from $53.4M a quarter earlier.
Buyers outnumbered sellers: 12 funds opened new BOLD positions and 4 closed out — a net gain of 8 holders — while 11 added to existing stakes and 17 trimmed.
The largest buyer was Vanguard Group, adding an estimated $618K. The largest seller was Millennium Management, exiting entirely with an estimated $908K sold.
- 55 institutional investors held Boundless Bio (BOLD) as of Q3 2024, up from 47 in Q2 2024.
- Funds reported $46.1M of Boundless Bio stock for Q3 2024, down 14% quarter-over-quarter.
- 12 funds opened new Boundless Bio positions in Q3 2024 and 4 closed out, a net change of +8 holders.
- The largest Boundless Bio buyer in Q3 2024 was Vanguard Group, an estimated $618K added.
- The largest Boundless Bio seller in Q3 2024 was Millennium Management, an estimated $908K sold.
Based on aggregated 13F filings for Q3 2024.